Close Menu

Gene Expression Research

The latest news about RNA-seq, gene expression profiling, and transcriptome sequencing.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.

The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.

NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.